We invite you to listen to an in-depth discussion of CIBRN Question #5 & Question #6, as presented by Dr. Gordon Searles, Dr. Ronald Vender and Dr. Mark Kirchhof, recorded at the CIBRN Dermatology Webinar, December 8, 2016. Link to recorded webinar.
CIBRN Question #5: Given that biosimilar trials are to be compared against the originator using a “most sensitive” indication or condition, how will the trial indication be selected for study? Link to discussion on Sosido.
CIBRN Question #6: Can the concept of extrapolation be used for biosimilars in patients with hidradenitis suppurativa given their major treatment differences? Link to discussion on Sosido.